FDA Closes 2013 With Flurry Of Citations For Misleading Rx Promotions
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of Prescription Drug Promotion issues 23 letters in 2013, five less than the previous year.
You may also be interested in...
FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.